2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1422

Identifying Generic and Specific Patients’ Perspectives on Disease- and Treatment-Related Issues in Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis: A Qualitative Concept Mapping Study
Abstract Number: 238

Identifying Immunoglobulin G4-Related Disease in Archived Pathological Specimens
Abstract Number: 2475

Identifying Key Variables for Inclusion in a Smartphone App to Support Clinical Care and Research in Patients with Rheumatoid Arthritis
Abstract Number: 1576

Identifying Rheumatoid Arthritis Subtypes Using Synovial Tissue Gene Expression Profiling, Histologic Scoring and Clinical Correlates
Abstract Number: 1121

IFN Regulatory Factor-5 Signaling Increases IFN-Gamma Production and Suppresses IL-2 Production from CD4+ T Cells, and Controls IgG Production in B Cells
Abstract Number: 3006

IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Abstract Number: 919

IL-17 Receptor a Signaling Impedes NF-ĸB p50/p50 Repressor and Subverts B-Cell Anergy in BXD2 Mice
Abstract Number: 1985

IL-18 Elevation in Macrophage Activation Syndrome: Human Evidence for a Chronic Set-Point and Murine Evidence for a Non-Hematopoietic Source
Abstract Number: 1910

IL-21 Inhibits Treg Differentiation and Function in SLE By Modulating GATA-3 and CTLA-4
Abstract Number: 2574

IL-22 As a Biomarker for Erosive Disease in Rheumatoid Arthritis
Abstract Number: 3036

IL-22 Is Dysregulated in Psoriatic Arthritis and Acts to Limit IFN-γ Driven Inflammatory Chemokine Production
Abstract Number: 1752

IL-23 Promotes the Generation of DNT Cells and Shifts the Balance Between IL-2 and IL-17 Production in Murine and Human SLE
Abstract Number: 821

IL-31 Is an Inflammatory Pro-Fibrotic Factor Elevated in a Subset of Scleroderma Patients with Severe Pruritus
Abstract Number: 69

IL-32 Promoter SNP rs4786370 Predisposed to Modified Lipoprotein Profiles in Patients with Rheumatoid Arthritis
Abstract Number: 2156

IL-6 and TNF-α Modulate Expressions of Cell Cycle Regulators of Rheumatoid Arthritis Fibroblast-like Synoviocytes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].